News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
The latest lung cancer research at ESTRO 24
Photo from ESTRO/X
Jul 19, 2024, 09:30

The latest lung cancer research at ESTRO 24

ESTRO shared on X:   .

“Discover the latest lung cancer research at ESTRO 24: highlights include the ETOP CHESS trial, SAKK 16/18 study, START-NEW-ERA outcomes, SYSTEMS-2 pain control, high-dose re-irradiation insights, and a stage III NSCLC trial on hypofractionation.”

Source: ESTRO/X

cancer ESTRO ETOP CHESS trial high-dose re-irradiation insights Lung cancer NSCLC OncoDaily Oncology START-NEW-ERA SYSTEMS-2 pain control
Special Coverage
Insight
Dec 22, 2024, 17:47
Next-gen immunotherapy is reshaping lung cancer treatment
Insight
Dec 22, 2024, 17:44
Erman Akkus: Local treatments of HCC, 2 recent studies
Blog
Dec 22, 2024, 17:39
Mark Cobbold: Incredible Year in Cell Therapy and Immunotherapy at AstraZeneca
Insight
Dec 22, 2024, 17:36
Nicholas Hornstein: Something new in BRAF V600E mCRC
Insight
Dec 22, 2024, 17:32
Fawzi Abu Rous: We launched Lung Cancer Alliance in Arabic-Speaking MENA
Science
Dec 22, 2024, 17:26
Andrea De Giglio: The prognostic role of STK11 mutations in advanced NSCLC treated with first-line IO
Science
Dec 22, 2024, 17:23
Zeynep Irem Ozay: Assessing nectin-4 as a predictive biomarker in GU malignancies
Science
Dec 22, 2024, 17:18
Sam Klempner: Proof of principle in KRAS G12C mutation in colorectal cancer
Blog
Dec 22, 2024, 17:07
Rahul Shah: A great 6 months of dose-dense learning in leukemia clinic at MD Anderson Cancer Center
Science
Dec 22, 2024, 17:03
Andrea Apolo: Several accruing Clinical Trials for patients with Small Cell Bladder Cancer
Insight
Dec 22, 2024, 16:56
GSK Announced Landmark Results from FIRST Trial in First-Line Advanced Ovarian Cancer
Insight
Dec 22, 2024, 16:50
NIH Funds $3.2 Million Study on the Combination of Immune Blockade and Antiangiogenic Agents in Cancer Treatment